A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study
✍ Scribed by A.K. GUPTA; C.W. LYNDE; H.C. JAIN; R.G. SIBBALD; B.E. ELEWSKI; C.R. DANIEL III; G.N. WATTEEL; R.C. SUMMERBELL
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 380 KB
- Volume
- 136
- Category
- Article
- ISSN
- 0007-0963
No coin nor oath required. For personal study only.
✦ Synopsis
There is some controversy about the prevalence of onychomycosis in patients with psoriasis compared to non-psoriatics. We therefore measured the prevalence of toenail onychomycosis in psoriatics and non-psoriatics attending dermatologists' offices. None of the patients had a referring diagnosis of onychomycosis. The prevalence of pedal onychomycosis in psoriatics (n = 561) was 13%. The odds of patients with psoriasis having onychomycosis was 56% greater than non-psoriatics of the same age and sex (P = 0.02). In the psoriatics, when the toenails were clinically abnormal, the prevalence of onychomycosis was 27%. The odds of developing onychomycosis increased with age (P < 0.0001) and the odds of men developing onychomycosis was 2.5 times that of women (P = 0.0001). The duration of psoriasis did not significantly affect the odds of developing onychomycosis. The fungal organisms recovered from psoriasis subjects with onychomycosis were similar to those in the normal population with onychomycosis (P = 0.58).
📜 SIMILAR VOLUMES
## Abstract ## Objective To evaluate the efficacy and safety of alefacept in combination with methotrexate (MTX) for the treatment of psoriatic arthritis (PsA). ## Methods Patients were eligible for this randomized, double‐blind, placebo‐controlled trial if they were ages 18–70 years and had act